Search
disease-modifying antirheumatic agent (DMARD)
Specific
abatacept (Orencia)
apremilast (Otezla)
auranofin [gold] (Ridaura)
aurothioglucose [gold] (Solganal)
azathioprine (Azanin, Imuran, Imurel)
baricitinib (Olumiant)
cyclophosphamide (Cytoxan, Neosar, Procytox {Canadian}) [CPM, CTX, CYT, NSC 26271]
cyclosporin A (Sandimmune, Neoral [CsA])
dapsone (Avlosulfon)
gold sodium thiomalate; aurothiomalate (Myochrysine, Chrysothios)
hydroxychloroquine (Plaquenil)
izokibep
leflunomide; teriflunomide (Arava)
methotrexate (Rheumatrex, MTX)
minocycline (Minocin, Solodyn, Emrosi)
mycophenolate (Cellcept, Myfortic)
oclacitinib maleate (Apoquel)
penicillamine (Cuprimine, Depen)
sulfasalazine (SSZ, Azulfidine, SAS)
tocilizumab; atlizumab (Actemra, RoActemra, Tofidence, Tyenne)
tofacitinib (Xeljanz)
General
pharmaceutical agent
References
- Medical Knowledge Self Assessment Program (MKSAP) 16
American College of Physicians, Philadelphia 2012
- Donahue KE, Gartlehner G, Jonas DE et al
Systematic review: comparative effectiveness and harms of
disease-modifying medications for rheumatoid arthritis.
Ann Intern Med. 2008 Jan 15;148(2):124-34
PMID: 18025440